Diagnostic Role of Tests for T Cell Receptor (TCR) Genes E Hodges, M T Krishna, C Pickard, J L Smith
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Dynamics of Individual T Cell Repertoires: from Cord Blood to Centenarians Olga V
Dynamics of Individual T Cell Repertoires: From Cord Blood to Centenarians Olga V. Britanova, Mikhail Shugay, Ekaterina M. Merzlyak, Dmitriy B. Staroverov, Ekaterina V. Putintseva, Maria A. This information is current as Turchaninova, Ilgar Z. Mamedov, Mikhail V. Pogorelyy, of September 27, 2021. Dmitriy A. Bolotin, Mark Izraelson, Alexey N. Davydov, Evgeny S. Egorov, Sofya A. Kasatskaya, Denis V. Rebrikov, Sergey Lukyanov and Dmitriy M. Chudakov J Immunol published online 13 May 2016 Downloaded from http://www.jimmunol.org/content/early/2016/05/12/jimmun ol.1600005 Supplementary http://www.jimmunol.org/content/suppl/2016/05/12/jimmunol.160000 http://www.jimmunol.org/ Material 5.DCSupplemental Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 27, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published May 13, 2016, doi:10.4049/jimmunol.1600005 The Journal of Immunology Dynamics of Individual T Cell Repertoires: From Cord Blood to Centenarians Olga V. -
Characterization of the T Cell Receptor Repertoire of Neonatal T Cells by RT-PCR and Single Strand Conformation Polymorphism Analysis
Bone Marrow Transplantation (2000) 26, 83–89 2000 Macmillan Publishers Ltd All rights reserved 0268–3369/00 $15.00 www.nature.com/bmt Characterization of the T cell receptor repertoire of neonatal T cells by RT-PCR and single strand conformation polymorphism analysis E Alfani1, AR Migliaccio2, M Sanchez1, AM Passarelli3 and G Migliaccio1 1Laboratory of Cell Biology and 2Clinical Biochemistry, Istituto Superiore di Sanita`, Rome; and 3Ospedale Civile Tivoli, Tivoli, Italy Summary: by other molecular mechanisms which include imprecise joining of V(D)J recombination,6 N-region diversification We have analyzed by reverse transcriptase-polymerase (random addition of nucleotides by terminal deoxy-ribonu- chain reaction (RT-PCR) the individual non-germ line cleotidyl transferase)7,8 and insertions of palindromic configurations of the T cell receptor (TCR) V chains nucleotides9 at specific points of the VD, DJ and VJ junc- expressed by T cells from eight individual cord blood tions. As a result of allele exclusion,10 each T cell clone specimens. cDNA from each cord blood was amplified expresses one and only one specifically rearranged TCR using a common primer coupled with a primer specific V chain. Therefore, the number of TCR V chain for each of 22 variable elements of the V chain family rearrangements expressed by a given population correlates and the amplified fragments were separated under high with its T cell clonality. resolution conditions. With cDNA from adult blood (as Cord blood (CB) has been proven to be a good source a control), all of the TCR chains were amplified as a of stem/progenitor cells for related and unrelated trans- smear consistent with the extensive polyclonality of plants.11,12 Successful engraftment with low graft-versus- adult T cells. -
Newborn Screening for Severe Combined Immunodeficiency and T-Cell Lymphopenia in California, 2010−2017 George S
Newborn Screening for Severe Combined Immunodeficiency and T-cell Lymphopenia in California, 2010–2017 George S. Amatuni, BS,a,b Robert J. Currier, PhD,a Joseph A. Church, MD,c Tracey Bishop,d Elena Grimbacher,e Alan Anh-Chuong Nguyen, MD,f Rajni Agarwal-Hashmi, MD,g Constantino P. Aznar, PhD,d Manish J. Butte, MD, PhD,h Morton J. Cowan, MD,a Morna J. Dorsey, MD, MMSc,a Christopher C. Dvorak, MD,a Neena Kapoor, MD,c Donald B. Kohn, MD,h M. Louise Markert, MD, PhD,i Theodore B. Moore, MD,h Stanley J. Naides, MD,j Stanley Sciortino, PhD, MPH,d Lisa Feuchtbaum, DrPH, MPH,d Rasoul A. Koupaei, PhD,d Jennifer M. Puck, MDa OBJECTIVES: Newborn screening for severe combined immunodeficiency (SCID) was instituted in abstract California in 2010. In the ensuing 6.5 years, 3 252 156 infants in the state had DNA from dried blood spots assayed for T-cell receptor excision circles (TRECs). Abnormal TREC results were followed-up with liquid blood testing for T-cell abnormalities. We report the performance of the SCID screening program and the outcomes of infants who were identified. METHODS: Data that were reviewed and analyzed included demographics, nursery summaries, TREC and lymphocyte flow-cytometry values, and available follow-up, including clinical and genetic diagnoses, treatments, and outcomes. RESULTS: Infants with clinically significant T-cell lymphopenia (TCL) were successfully identified at a rate of 1 in 15 300 births. Of these, 50 cases of SCID, or 1 in 65 000 births (95% confidence interval 1 in 51 000–1 in 90 000) were found. -
Distorted TCR Repertoires Define Multisystem Inflammatory Syndrome in Children
medRxiv preprint doi: https://doi.org/10.1101/2021.04.12.21255098; this version posted April 15, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Distorted TCR repertoires define multisystem inflammatory syndrome in children Amna Malik* 1, Eszter N. Tóth* 2, Michelle S. Teng 2, Jacob Hurst 2, Eleanor Watt 3, Lauren Wise 4, Natalie Kent 4, Jack Bartram 5, Louis GranDjean 6, Margarita Dominguez-Villar 7, Stuart ADams† 4 anD Nichola Cooper† 1 1 Centre for Haematology, Department of Immunology anD Inflammation, Imperial College LonDon, LonDon, UniteD KingDom 2 Etcembly Ltd, MagDalen Centre, Robert Robinson Way, OxforD, UniteD KingDom 3 Molecular anD Cellular Immunology Department, UCL Great OrmonD Street Institute of ChilD Health, LonDon, UniteD KingDom 4 SIHMDS-Haematology, Great OrmonD Street Hospital for ChilDren, LonDon, UniteD Kingdom 5 Department of Haematology, Great OrmonD Street Hospital for ChilDren, LonDon, UniteD Kingdom 6 PaeDiatric Infectious Diseases, Great OrmonD Street Hospital for ChilDren, LonDon, UniteD Kingdom 7 Department of Infectious Diseases, Imperial College LonDon, LonDon, UniteD KingDom *These authors have contributed equally to this work †These authors have jointly supervised CorresponDing author: Nichola Cooper Tel: +44 20 3313 4017 E-mail: [email protected] KeyworDs: Sars-Cov2, coronavirus, COVID-19, multisystem inflammatory synDrome, MIS-C, superantigen, TCR, immune repertoire, sequencing NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. -
Defining Natural Antibodies
PERSPECTIVE published: 26 July 2017 doi: 10.3389/fimmu.2017.00872 Defining Natural Antibodies Nichol E. Holodick1*, Nely Rodríguez-Zhurbenko2 and Ana María Hernández2* 1 Department of Biomedical Sciences, Center for Immunobiology, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, United States, 2 Natural Antibodies Group, Tumor Immunology Division, Center of Molecular Immunology, Havana, Cuba The traditional definition of natural antibodies (NAbs) states that these antibodies are present prior to the body encountering cognate antigen, providing a first line of defense against infection thereby, allowing time for a specific antibody response to be mounted. The literature has a seemingly common definition of NAbs; however, as our knowledge of antibodies and B cells is refined, re-evaluation of the common definition of NAbs may be required. Defining NAbs becomes important as the function of NAb production is used to define B cell subsets (1) and as these important molecules are shown to play numerous roles in the immune system (Figure 1). Herein, we aim to briefly summarize our current knowledge of NAbs in the context of initiating a discussion within the field of how such an important and multifaceted group of molecules should be defined. Edited by: Keywords: natural antibody, antibodies, natural antibody repertoire, B-1 cells, B cell subsets, B cells Harry W. Schroeder, University of Alabama at Birmingham, United States NATURAL ANTIBODY (NAb) PRODUCING CELLS Reviewed by: Andre M. Vale, Both murine and human NAbs have been discussed in detail since the late 1960s (2, 3); however, Federal University of Rio cells producing NAbs were not identified until 1983 in the murine system (4, 5). -
U Klein Lecture 3
Introduction to Immunology Antigen Receptors and Generation of Antibody and T-Cell Receptor Diversity Ulf Klein [email protected] Adaptive Immunity The Adaptive or Acquired Immune Respone: • Is the response of antigen-specific lymphocytes to antigen, including the development of immunological memory • Are mediated by the clonal selection of antigen-specific lymphocytes • Immunoglobulins and T-cell receptors are the highly variable recognition molecules of adaptive immunity Effector Molecules of Adaptive Immunity The Antibodies Made Against a Pathogen Are Highly Specific for That Pathogen The Diversity of Antibodies and T-Cell Receptors Is Generated by Gene Rearrangement Through Somatic DNA Recombination Gene Rearrangement Produces a Diversity of Antigen Receptors in Lymphocytes Clonal Selection of B and T Lymphocytes 1. 3. 2. 4. The Immunoglobulin Molecule: • Made up of 2 identical heavy chains and 2 identical light chains • The antibody molecule has 2 functional domains Features of the Immunoglobulin Molecule • The flexible hinge allows it to bind with both arms to antigens on the surfaces of pathogens • The heavy and light chains are made from a series of similar protein domains The Hypervariable Regions of Antibody V Domains Lie in Discrete Loops at One End of the Domain Structure • The hypervariable loops contribute much of the antigen specificity of the antigen-binding site Hypervariable Regions in Heavy and Light-Chains Antigen-Binding Sites Can Have Diverse Structures • Epitopes of antigens can bind to pockets, grooves, extended -
Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency
Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck. -
Current Perspectives on Primary Immunodeficiency Diseases
Clinical & Developmental Immunology, June–December 2006; 13(2–4): 223–259 Current perspectives on primary immunodeficiency diseases ARVIND KUMAR, SUZANNE S. TEUBER, & M. ERIC GERSHWIN Division of Rheumatology, Allergy and Clinical Immunology, Department of Internal Medicine, University of California at Davis School of Medicine, Davis, CA, USA Abstract Since the original description of X-linked agammaglobulinemia in 1952, the number of independent primary immunodeficiency diseases (PIDs) has expanded to more than 100 entities. By definition, a PID is a genetically determined disorder resulting in enhanced susceptibility to infectious disease. Despite the heritable nature of these diseases, some PIDs are clinically manifested only after prerequisite environmental exposures but they often have associated malignant, allergic, or autoimmune manifestations. PIDs must be distinguished from secondary or acquired immunodeficiencies, which are far more common. In this review, we will place these immunodeficiencies in the context of both clinical and laboratory presentations as well as highlight the known genetic basis. Keywords: Primary immunodeficiency disease, primary immunodeficiency, immunodeficiencies, autoimmune Introduction into a uniform nomenclature (Chapel et al. 2003). The International Union of Immunological Societies Acquired immunodeficiencies may be due to malnu- (IUIS) has subsequently convened an international trition, immunosuppressive or radiation therapies, infections (human immunodeficiency virus, severe committee of experts every two to three years to revise sepsis), malignancies, metabolic disease (diabetes this classification based on new PIDs and further mellitus, uremia, liver disease), loss of leukocytes or understanding of the molecular basis. A recent IUIS immunoglobulins (Igs) via the gastrointestinal tract, committee met in 2003 in Sintra, Portugal with its kidneys, or burned skin, collagen vascular disease such findings published in 2004 in the Journal of Allergy and as systemic lupus erythematosis, splenectomy, and Clinical Immunology (Chapel et al. -
HLA Class I-Associated Expansion of TRBV11-2 T Cells in Multisystem Inflammatory Syndrome in Children
HLA class I-associated expansion of TRBV11-2 T cells in Multisystem Inflammatory Syndrome in Children Rebecca A. Porritt, … , Mascha Binder, Moshe Arditi J Clin Invest. 2021. https://doi.org/10.1172/JCI146614. Research In-Press Preview COVID-19 Immunology Graphical abstract Find the latest version: https://jci.me/146614/pdf HLA Class I-associated expansion of TRBV11-2 T cells in Multisystem Inflammatory Syndrome in Children Rebecca A Porritt1,2,*, Lisa Paschold3,*, Magali Noval Rivas1,2,4, Mary Hongying Cheng5, Lael M Yonker6, Harsha Chandnani7, Merrick Lopez7, Donjete Simnica3, Christoph Schultheiß3, Chintda Santiskulvong8, Jennifer Van Eyk9, John K. McCormick10, Alessio Fasano6, Ivet Bahar5,ǂ, Mascha Binder3,ǂ and Moshe Arditi1,2,4,9,ǂ,† 1 Departments of Pediatrics, Division of Infectious Diseases and Immunology, Infectious and Immunologic Diseases Research Center (IIDRC) and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA 2 Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA 3 Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle- Wittenberg, 06120 Halle (Saale), Germany 4 Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 5 Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA 6 Mucosal Immunology and Biology Research Center and Department of Pediatrics, Boston, Massachusetts General Hospital, MA, USA 7 Department of Pediatrics, Loma Linda University Hospital, CA, USA 8 Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA 9 Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA 10 Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada. -
ESID Registry – Working Definitions for Clinical Diagnosis of PID
ESID Registry – Working Definitions for Clinical Diagnosis of PID These criteria are only for patients with no genetic diagnosis*. *Exceptions: Atypical SCID, DiGeorge syndrome – a known genetic defect and confirmation of criteria is mandatory. Available entries (Please click on an entry to see the criteria.) Page Acquired angioedema .................................................................................................................................................................. 4 Agammaglobulinemia .................................................................................................................................................................. 4 Asplenia syndrome (Ivemark syndrome) ................................................................................................................................... 4 Ataxia telangiectasia (ATM) ......................................................................................................................................................... 4 Atypical Severe Combined Immunodeficiency (Atypical SCID) ............................................................................................... 5 Autoimmune lymphoproliferative syndrome (ALPS) ................................................................................................................ 5 APECED / APS1 with CMC - Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) .................. 5 Barth syndrome ........................................................................................................................................................................... -
Blueprint Genetics Severe Combined Immunodeficiency Panel
Severe Combined Immunodeficiency Panel Test code: IM0101 Is a 80 gene panel that includes assessment of non-coding variants. Is ideal for patients with a clinical suspicion of combined immunodeficiencies. The genes on this panel are included in the Primary Immunodeficiency Panel. About Severe Combined Immunodeficiency Severe combined immunedeficiencies (SCIDs) are a group of primary immunodeficiencies characterized by specific mutations in genes of T and B-lymphocyte systems and leading to little or no immune response. Different subtypes of SCIDs are characterized and subdivided by the presence of circulating T and B cells. T cells are absent or markedly decreased in the most types, but levels of B cells vary. In addition, both of these disease subgroups (T-B+ and T-B-) can occur with or without NK cells. Patients with SCID are susceptible to recurrent infections that can be fatal. The worldwide prevalence of SCID is estimated to be at least 1:100,000 births, while some genetically more homogenous populations may show markedly increased numbers. Mutations in IL2RG are the most common reason for SCIDs, explaining approximately 50% of all cases and close to 100% of X-linked cases. Availability 4 weeks Gene Set Description Genes in the Severe Combined Immunodeficiency Panel and their clinical significance Gene Associated phenotypes Inheritance ClinVar HGMD ADA Severe combined immunodeficiency due to adenosine deaminase AR 49 93 deficiency AK2 Reticular dysgenesis AR 14 17 ATM Breast cancer, Ataxia-Telangiectasia AD/AR 1047 1109 BCL11B Immunodeficiency -
A Case Report of Neonatal Omenn Syndrome Presenting As Striking Erythroderma
Open Access Journal of Pediatrics & Child Health Care Case Report A Case Report of Neonatal Omenn Syndrome Presenting as Striking Erythroderma Duan XY1, Zhao QQ2 and Wei H2* 1Department of Neonatology, Children′s Hospital of Abstract Chongqing Medical University, China Background: Omenn Syndrome (OS) is a kind of Serious Combined 2Department of Neonatology, Children′s Hospital of Immunodeficiency Disease (SCID). A variety of genetic defects responsible for Chongqing Medical University, China lymphocyte or thymic development can give rise to OS, of which the Recombinase- *Corresponding author: Wei H, Medical Doctor, Activating Genes (RAG1 and RAG2) being the best characterised. It is often Department of Neonatology, Children’s Hospital of misdiagnosed and progressively deteriorated due to the limit knowledge in early Chongqing Medical University, Chongqing Medical life of children. University, Postal Address: No.136, Zhong Shan 2nd Case Presentation: We present herein a typical case of Omenn syndrome Road, Yuzhong District, Chongqing, 400014, China that initially manifested as diffuse erythroderma in a 2-day-old newborn. Received: May 13, 2020; Accepted: June 05, 2020; Conclusions: The age of Omenn syndrome onset was earlier. Typical clinical Published: June 12, 2020 features include erythroderma and immune dysfunction. Immunodeficiency must be considered in every case of neonatal erythroderma and immunological evaluation should be performed as soon as possible. Genetic study confirms the diagnose. We found two novel mutations in RAG1 could cause Omenn syndrome. Keywords: Neonate; Omenn syndrome; SCID; Erythroderma Introduction crying and sucking force are good, bowel movement and urination are as usual. The child was the 4th fetus and the 2nd birth, cesarean Omenn Syndrome (OS) is a form of Severe Combined delivery due to “giant”, birth weight was 3575g, apgar score was Immunodeficiency Disease (SCID) characterized by erythroderma, normal, formula milk feeding, no history of blood transfusion, and hepatosplenomegaly, lymphadenopathy, and alopecia.